Anika Therapeutics, Inc. (ANIK)
21.31
-0.47
(-2.16%)
USD |
NASDAQ |
Aug 24, 16:00
21.31
0.00 (0.00%)
After-Hours: 20:00
Anika Therapeutics Enterprise Value : 278.32M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 278.32M |
| August 20, 2026 | 272.43M |
| August 19, 2026 | 271.36M |
| August 18, 2026 | 275.51M |
| August 17, 2026 | 274.17M |
| August 14, 2026 | 274.57M |
| August 13, 2026 | 270.16M |
| August 12, 2026 | 281.67M |
| August 11, 2026 | 270.96M |
| August 10, 2026 | 263.60M |
| August 07, 2026 | 273.50M |
| August 06, 2026 | 256.64M |
| August 05, 2026 | 243.66M |
| August 04, 2026 | 249.28M |
| August 03, 2026 | 264.33M |
| July 31, 2026 | 244.86M |
| July 30, 2026 | 228.67M |
| July 29, 2026 | 203.24M |
| July 28, 2026 | 189.59M |
| July 27, 2026 | 187.85M |
| July 24, 2026 | 186.91M |
| July 23, 2026 | 183.17M |
| July 22, 2026 | 187.72M |
| July 21, 2026 | 189.72M |
| July 20, 2026 | 188.39M |
| Date | Value |
|---|---|
| July 17, 2026 | 190.93M |
| July 16, 2026 | 198.56M |
| July 15, 2026 | 200.03M |
| July 14, 2026 | 194.54M |
| July 13, 2026 | 197.89M |
| July 10, 2026 | 195.61M |
| July 09, 2026 | 202.17M |
| July 08, 2026 | 205.52M |
| July 07, 2026 | 199.23M |
| July 06, 2026 | 201.37M |
| July 02, 2026 | 192.40M |
| July 01, 2026 | 189.99M |
| June 30, 2026 | 182.63M |
| June 29, 2026 | 185.20M |
| June 26, 2026 | 186.41M |
| June 25, 2026 | 180.00M |
| June 24, 2026 | 181.46M |
| June 23, 2026 | 179.59M |
| June 22, 2026 | 174.39M |
| June 18, 2026 | 177.32M |
| June 17, 2026 | 174.79M |
| June 16, 2026 | 175.72M |
| June 15, 2026 | 179.86M |
| June 12, 2026 | 181.33M |
| June 11, 2026 | 181.33M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Perspective Therapeutics, Inc. | 143.57M |
| MiMedx Group, Inc. | 512.35M |
| ABVC BioPharma, Inc. | 28.48M |
| Enovis Corp. | 2.861B |
| Edwards Lifesciences Corp. | 48.33B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.309M |
| Revenue (Quarterly) | 32.61M |
| Total Expenses (Quarterly) | 29.30M |
| EPS Diluted (Quarterly) | 0.2412 |
| Gross Profit Margin (Quarterly) | 65.15% |
| Profit Margin (Quarterly) | 10.15% |
| Earnings Yield | -1.29% |
| Normalized Earnings Yield | -1.286 |